116 Jacquet P., Sugarbaker P.H.: Peritoneal-plasma barrier. In: Sugarbaker Ph (ed). Peritoneal Carcinomatosis: Principles of management. Boston, Kluwer Academic Publishers, pp: 53-63, 1966.
117 Deraco M., Vaglini M., Santinami M., Costagli V., Di Re F., Inglese M.G., Mascotti G., Persiani L., Santoro N., Sequeira C., Carlier-Somers D.: Razionale per un trattamento chemioipertermico della carcinosi peritoneale. Argomenti di Oncologia, 16: 149-159, 1995.
118 Kuzu M, Koksoy C, Kale T, Demirpence E, Renda N. Experimental study of the effect of preoperative 5-fluorouracil on the integrity of colon anastomosis. Br J Surg, 1998;85:236-9.
119 Fumagalli U, Trabucchi E, Soligo M, Rosati R, Rebuffat C, Tonelli C et al. Effects of intraperitoneal chemotherapy on anastomotic healing in rats. J Surg Res 1991;50:82-7.
120 The effect of intraperitoneal paclitaxel administration on colonic anastomosis. Arikan AY, Gunal O, Pehlivan M, Alper M. Hepatogastroenterology 2000 Sep-Oct;47(35):1273-6.
121 Shimizu T, Maeta M, Koga. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 1991;78:57-9.
122 Zanon C, Clara R, Bortolini M, Malossi A, Moscato R, Celoria P, de Andrea M, Rizzo M, Chiappino I, Grazia Sciuto M, Mussa ª Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis. Int J Hyperthermia 2001 Sep-Oct;17(5):456-64.
123 Sugarbaker PH, Jacquet P, Stephens AD, Stuart OA, Averbach AM. Comparison of covered versus closed technique for heated intraoperative chemotherapy for peritoneal carcinomatosis from gastrointestinal cancer. In: Abe O, Inokuchi K,Takasaki K, eds. XXX World congress of the International College of surgeons. Bologna, Italy: Monduzzi Editore, 1996:389-93.
124 Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response.Cancer Res. 1992 Jan 15;52(2):487-90.
125 Milosevic MF, Fyles AW, Hill RP The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1111-23.
126 Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32.
127 Deraco M, S Kusamura. Peritonectomy and Intraperitoneal Hypertermic Perfusion in the treatment of peritoneal mesothelioma, pseudomyxoma peritonei and abdominal sarcoma. Sitilo Congress. Pisa, Italy, June, 2001.
128 van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huinink WW, Beijnen JH. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000 Nov;26(7):663-8.
129 Steller M.A., Egorin M.J., Trimble E.L., Bartlett D.L., Zuhowski E.G., Alexander H.R., Dedrick R.L.: A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol., 43: 106-114, 1999.
130 Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, Palumbo M, De Paoli M, Corsini A. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000;45:457-462.
131 Wiltshaw E, Kroner T. Phase II trial of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55-60, 1976.
132 Gershenson DM, Wharton JT, Herson J, Edwards CL, Rutledge FN. Single-agent cis-platinum therapy for advanced ovarian cancer. Obstet Gynecol 1981 Oct;58(4):487-96
133 Ehrlich CE, Einhorn L, Williams SD, Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep 1979 Feb;63(2):281-8.
134 Omura G, Ehrlich CE, Blessing JA, et al. A randodmized trial of cyclophosphamide plus Adiamycin - with or without cisplatin in ovarian carcinoma. Proc Am Soc Clin Oncol 1:109, 1982.
135 Nejt JP, ten Bokkel Hunink WW. Randomized trial comparing two combination chemotherapy regimens (HEXAcaf versus CHAP-5) in advanced ovarian carcinoma. Lancet 2:594-600, 1984.
136 Vogl SE, Berenzweig M, Kaplan BH, Moukhtar M, and Bulkin W. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelanine, Adriamycin, and cis-dichlorodiammineplatinum (II). Cancer Treat Rep 63:311-7, 1979.
137 Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 3:1455-1462,1985.
138 Omura GA, Blessing JA, Ehrlich CE et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 57:1725-1730, 1986.
139 Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br Med J 303:884-893, 1991.
140 Bartlett DL, Buell JF, Libutti SK, Reed E, Bo Lee Kang, Figg WD, Venzon DJ, Alexander HR. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998; 83(6):1251-1261.
141 Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472-7.
142 Masuda H, Tanaka T, Matsushima S. Hyperthermic enhancement of cisplatin-induced generation of active oxygen radicals in a cell-free system. Anticancer Res 1998;18:1473-7.
143 Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hyperthermia 1997;13:439-57.
144 Cohen CJ. Surgical considerations in ovarian cancer. Semi Oncol 1985,12,53-6.
145 Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983,43,1426-1431.
146 ten Bokkel Huinink WW, Dubbelma R, Aartsen A, Franklin H, Mcvie JG. Experimental and clinical results of intraperitoneal cisplatin. Semin Oncol 1985,12,43-6.
147 Pretorius RG, Hacker HF, Berek JS et al. Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 1983,67,1085-1092.
148 ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, Mcvie JG. Intraperitoneal carboplatina for refractory ovarian cancer: phase I study. Proceedings of the Second International Conference of intracavitary Chemotherapy, p.47, San Diego, 1988.
149 Los G, McVie JG. Carboplatin: an alternative for intraperitoneal cisplatin treatment in cancers restricted to the peritoneal cavity? Proc Am Soc Clin Oncol 1990, abstract 608.
150 Speyer J, Beller U, Colombo N et al. A phase I trial of intraperitoneal carboplatin (CBDCA) in women with ovarian cancer. Proceedings of the second International Conference of Intracavitary Chemotherapy, p.120, San Diego, 1988.
151 Pfeiffer P, Bennendbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990,36,306-311.
152 Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998;41(2):147-54
153 Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC.Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979 Aug;39(8):3209-14.
154 Ozols RF, Young RC, speyer JL et al. Phase I and pharmacological studies of adrimycin administered intraperitoneally to patients with ovarian cancers. Cancer Res 1982, 42, 4265-9.
155 Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 1998 Nov-Dec;84(6):706-11
156 Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2',2'-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995 Sep 4;62(5):627-30
157 Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies. J Surg Oncol 2001 Feb;76(2):106-14.
158 Los G, Mutsaers PH, Ruevekamp M, McVie JG. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett 1990 May 30;51(2):109-17.
159 Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992 Sep;10(9):1485-91.
160 Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001 May;62(4):208-12.
161 Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal Paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620-4.
162 Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil; pharmacokinetics studies. Oncology 1998;55:130-8.
163 Howell SB, Chu BB, Wung WE, Metha BM, Mendelson J. Long duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 1981,67,1161-1170.
164. Sugarbaker PH, Gianola FJ, Speyer JL, Wesly R, Barofsky I, MyersCE. Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with a primary colon or rectal cancer. Semin Oncol, 1985, 12, 101-111.
165 Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001;11 Suppl 1:57-63.
166 Dembo AJ, Bush RS. Current concepts in cancer: ovary - treatment of stage III and IV: choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys 1982; 8:893-7.
167 Day TG Jr. Gallager HS, Rutledge FN. Epithelial carcinoma of ovary: prognostic importance of histology grade. National Cancer Institute monograph series. No. 42. Washington, D.C.: Government Printing Office, 1975:15-21.
168 Jacquet P., Sugarbaker P.H.: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res., 15: 49-58, 1996.
169 Better reporting of randomised controlled trials: the CONSORT statement. BMJ 313:50-571, 1996.
170 Altman D.G., Schulz K.F. Concealment treatment allocation in randomised trials. BMJ, 323:446-7, 2001.
171 Schulz K.F. Randomised trials, human nature, and reporting guidelines. Lancet, 348:596-8, 1996.
172 Schulz K.F., Grimes D., Altman D.G., Hayes R.J. Blinding and exclusions after allocation in randomised controlled trials; a survey of published parallel group trials in obstetrics and gynaecology. BMJ,312:742-4, 1996.
173 Sugarbaker PH. Laser-mode electrosurgery. Cancer Treat Res. 1996;82:375-85.
174 Rossi CR, Foletto M, Mocellin S, Pilati PL, De Simone M, Deraco M, Cavaliere F, Palatini P, Guasti F, Scalerta R, Lise M. Hyperthermic Intraoperative Intraperitoneal Chemotherapy with Cisplatin and Doxorubicin in patients who undergo Cytoreductive Surgery for Peritoneal Carcinomatosis and Sarcomatosis. Cancer, 94: 492-499; 2002.
175 Vaglini M, Deraco M, Santinami M, Re F, Inglese MG, Manzi R, Persiani L, Santoro N, Sequeira C, Sala S, Somers DC, Stefanon B. Chemioipertermia intraperitoneale; tecnica chirurgica. Argomenti di Oncologia, 16: 161-167, 1995.
176 Koga S., Hamazoe R., Maeta M., Shimizu N., Murakami A and Wakatsuki t. Prophylatic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic perfusion with MMC. Cancer 61;232-237, 1988. 70
177 Gilly F.N., Carry P.Y., Sayag A.C., et al. Traitement des carcinoses péritonéales par chimio-hyperthermic intra-péritonéale avec MMC. Première expérience. Ann Chir 44:545-551, 1990. 71
178 Berny C., Mialon A., Manchon M., Le K.E., Panteix G., Baltassat P., Gilly F.N. Carry P.Y. Sayag A. and Braillon G. Biochemical modifications in the blood and the heated fluids during intraperitoneal chemohyperthemia. Oncology 50: 362-365, 1993.
179 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-81, 1958.
180 Mantel N. Evaluation of survival data ad two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-70, 1966.
181 Cox DR. Regression models and life-tables. J R Stat Soc 1972;B34:187-202.
182 Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14:1707-23.
183 Bartolucci A. Estimation and comparison of proportions. In Buyse M., Sylvester R., editors. Cancer clinical trials, methods and practice. Oxford (UK); Oxford University Press; 1984. p 337-60.
184 Kruskal W.H., Wallis W.A. Use of ranks in one criterion variance analysis. J Am Stat Assoc 1952;47:583-92.
185 WORLD MEDICAL ASSOCIATION - Declaration of Helsinki (1964), 1996.

1- 2 - 3 - 4 - 5 - 6 - 7